Current status and future prospects for a vaccine against American trypanosomiasis

References

• World Health Organization. Control of Chagas disease: second report of the WHO expert committee. Geneva, Switzerland (2002).
   Google Scholar
• Kirchhoff LV. American trypanosomiasis (Chagas’ disease) - a tropical disease now in the United States. N. Engl. J. Med. 329, 639–644 (1993).
   PubMed Web of Science ®Google Scholar
• Kirchhoff LV, Weiss LM, Wittner M, Tanowitz HB. Parasitic diseases of the heart. Front. Biosci. 9, 706–723 (2004).
   PubMed Web of Science ®Google Scholar
• Shulman IA, Appleman MD, Saxena S, Hiti AL, Kirchhoff LV. Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion 37, 727–731 (1997).
   PubMedGoogle Scholar
• Leiby DA, Rentas FJ, Nelson KE et al. Evidence of Trypanosoma cruzi infection (Chagas’ disease) among patients undergoing cardiac surgery. Circulation 102, 2978–2982 (2000).
   PubMedGoogle Scholar
• Leiby DA, Herron RM Jr, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 42, 549–555 (2002).
   PubMed Web of Science ®Google Scholar
• Dodd RY, Leiby DA. Emerging infectious threats to the blood supply. Ann. Rev. Med. 55, 191–207 (2004).
   PubMed Web of Science ®Google Scholar
• Beard CB, Pye G, Steurer FJ et al. Chagas disease in a domestic transmission cycle, southern Texas, USA. Emerg. Infect. Dis. 9, 103–105 (2003).
   PubMedGoogle Scholar
• Shadomy SV, Waring SC, Chappell CL. Combined use of enzyme-linked immunosorbent assay and flow cytometry to detect antibodies to Trypanosoma cruzi in domestic canines in Texas. Clin. Diagn. Lab. Immuno.l 11, 313–319 (2004).
   PubMedGoogle Scholar
• Beard CB, Young DG, Butler JF, Evans DA. First isolation of Trypanosoma cruzi from a wild-caught Triatoma sanguisuga (LeConte) (Hemiptera: Triatominae) in Florida, USA. J. Parasitol. 74, 343–344 (1988).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Chagas disease after organ transplantation - United States, 2001. JAMA287, 1795–1796 (2002).
   PubMedGoogle Scholar
• Brisse S, Dujardin JC, Tibayrenc M. Identification of six Trypanosoma cruzi lineages by sequence-characterised amplified region markers. Mol. Biochem. Parasitol. 111, 95–105 (2000).
   PubMedGoogle Scholar
• Brisse S, Verhoef J, Tibayrenc M. Characterization of large and small subunit rRNA and mini-exon genes further support the distinction of six Trypanosoma cruzi lineages. Int. J. Parasitol. 31, 1218–1226 (2001).
   PubMed Web of Science ®Google Scholar
• Barnabe C, Neubauer K, Solari A, Tibayrenc M. Trypanosoma cruzi: presence of the two major phylogenetic lineages and of several lesser discrete typing units (DTUs) in Chile and Paraguay. Acta. Trop. 78, 127–137 (2001).
   PubMedGoogle Scholar
• Bosseno MF, Barnabe C, Magallon Gastelum E et al. Predominance of Trypanosoma cruzi lineage I in Mexico. J. Clin. Microbiol. 40, 627–632 (2002).
   PubMedGoogle Scholar
• Barnabe C, Yaeger R, Pung O, Tibayrenc M. Trypanosoma cruzi: a considerable phylogenetic divergence indicates that the agent of Chagas disease is indigenous to the native fauna of the United States. Exp. Parasitol. 99, 73–79 (2001).
   PubMedGoogle Scholar
• Rossi MA, Ramos SG, Bestetti RB. Chagas’ heart disease: clinical-pathological correlation. Front Biosci. 8, E94–E109 (2003).
   PubMed Web of Science ®Google Scholar
• Rocha MO, Ribeiro AL, Teixeira MM. Clinical management of chronic Chagas cardiomyopathy. Front Biosci. 8, E44–E54 (2003).
   PubMed Web of Science ®Google Scholar
• Gomes ML, Galvao LM, Macedo AM, Pena SD, Chiari E. Chagas’ disease diagnosis: comparative analysis of parasitologic, molecular, and serologic methods. Am. J. Trop. Med. Hyg. 60, 205–210 (1999).
   PubMed Web of Science ®Google Scholar
• Portela-Lindoso AA, Shikanai-Yasuda MA. Chronic Chagas’ disease: from xenodiagnosis and hemoculture to polymerase chain reaction. Rev. Saude. Publica. 37, 107–115 (2003).
   PubMedGoogle Scholar
• Andersson J. Molecular diagnosis of experimental Chagas disease. Trends Parasitol. 20, 52–53 (2004).
   PubMedGoogle Scholar
• Gonzalez N, Galindo I, Guevara P et al. Identification and detection of Trypanosoma cruzi by using a DNA amplification fingerprint obtained from the ribosomal intergenic spacer. J. Clin. Microbiol. 32, 153–158 (1994).
   PubMedGoogle Scholar
• Schofield CJ, Dias JC. The Southern Cone initiative against Chagas disease. Adv. Parasitol. 42, 1–27 (1999).
   PubMed Web of Science ®Google Scholar
• Dias J, Schofield C. The evolution of Chagas disease (American trypanosomiasis) control after 90 years since Carlos Chagas discovery. Mem. Inst. Oswaldo Cruz 94(Suppl. 1), 103–121 (1999).
   PubMedGoogle Scholar
• Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin. Microbiol. Rev. 18, 12–29 (2005).
   PubMed Web of Science ®Google Scholar
• de Andrade AL, Zicker F, de Oliveira RM et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet348, 1407–1413 (1996).
   PubMed Web of Science ®Google Scholar
• Coura JR. Current prospects of specific treatment of Chagas’ disease. Bol. Chil. Parasitol. 51, 69–75 (1996).
   PubMedGoogle Scholar
• Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz 97, 3–24 (2002).
   PubMed Web of Science ®Google Scholar
• Leon JS, Engman DM. Autoimmunity in Chagas heart disease. Int. J. Parasitol. 31, 555–561 (2001).
   PubMed Web of Science ®Google Scholar
• Leon JS, Engman DM. The significance of autoimmunity in the pathogenesis of Chagas heart disease. Front Biosci. 8, e315–322 (2003).
   PubMed Web of Science ®Google Scholar
• Girones N, Fresno M. Etiology of Chagas disease myocarditis: autoimmunity, parasite persistence, or both? Trends Parasitol. 19, 19–22 (2003).
   PubMed Web of Science ®Google Scholar
• Iwai LK, Juliano MA, Juliano L, Kalil J, Cunha-Neto E. T-cell molecular mimicry in Chagas disease: identification and partial structural analysis of multiple cross-reactive epitopes between Trypanosoma cruzi B13 and cardiac myosin heavy chain. J. Autoimmun. 24, 111–117 (2005).
   PubMedGoogle Scholar
• Higuchi MD, Benvenuti LA, Martins Reis M, Metzger M. Pathophysiology of the heart in Chagas’ disease: current status and new developments. Cardiovasc. Res. 60, 96–107 (2003).
   PubMed Web of Science ®Google Scholar
• Lane JE, Olivares-Villagomez D, Vnencak-Jones CL, McCurley TL, Carter CE. Detection of Trypanosoma cruzi with the polymerase chain reaction and in situ hybridization in infected murine cardiac tissue. Am. J. Trop. Med. Hyg. 56, 588–595 (1997).
   PubMedGoogle Scholar
• Wincker P, Telleria J, Bosseno MF et al. PCR-based diagnosis for Chagas’ disease in Bolivian children living in an active transmission area: comparison with conventional serological and parasitological diagnosis. Parasitology 114(Pt. 4), 367–373 (1997).
   PubMedGoogle Scholar
• Anez N, Carrasco H, Parada H et al. Myocardial parasite persistence in chronic chagasic patients. Am. J. Trop. Med. Hyg. 60, 726–732 (1999).
   PubMed Web of Science ®Google Scholar
• Mortara RA, da Silva S, Taniwaki NN. Confocal fluorescence microscopy: a powerful tool in the study of Chagas’ disease. Rev. Soc. Bras. Med. Trop. Res. 33, 79–82 (2000).
   PubMedGoogle Scholar
• Salomone OA, Juri D, Omelianiuk MO et al. Prevalence of circulating Trypanosoma cruzi detected by polymerase chain reaction in patients with Chagas’ cardiomyopathy. Am. J. Cardiol. 85, 1274–1276 (2000).
   PubMedGoogle Scholar
• Monteon-Padilla V, Hernandez-Becerril N, Ballinas-Verdugo MA, Aranda-Fraustro A, Reyes PA. Persistence of Trypanosoma cruzi in chronic chagasic cardiopathy patients. Arch. Med. Res. 32, 39–43 (2001).
   PubMedGoogle Scholar
• Caliari MV, de Lana M, Caja RA et al. Immunohistochemical studies in acute and chronic canine chagasic cardiomyopathy. Virchows Arch. 441, 69–76 (2002).
   PubMedGoogle Scholar
• Rocha A, de Meneses AC, da Silva AM et al. Pathology of patients with Chagas’ disease and acquired immunodeficiency syndrome. Am. J. Trop. Med. Hyg. 50, 261–268 (1994).
   PubMed Web of Science ®Google Scholar
• Sartori AM, Lopes MH, Caramelli B et al. Simultaneous occurrence of acute myocarditis and reactivated Chagas’ disease in a patient with AIDS. Clin. Infect. Dis. 21, 1297–1299 (1995).
   PubMed Web of Science ®Google Scholar
• Jardim E, Takayanagui OM. Chagasic meningoencephalitis with detection of Trypanosoma cruzi in the cerebrospinal fluid of an immunodepressed patient. J. Trop. Med. Hyg. 97, 367–370 (1994).
   PubMedGoogle Scholar
• D’Almeida P, Keitel E, Bittar A et al. Long-term evaluation of kidney donors. Transplant Proc. 28, 93–94 (1996).
   PubMedGoogle Scholar
• Muniz J, Freitas G. Ensaios de vacinacao preventive e cyrativa nas infeccoes pelo Schizotrypanum cruzi. Mem. Inst. Oswaldo Cruz44, 529–541 (1946).
   Google Scholar
• Kagan IG, Norman L. Immunologic studies on Trypanosoma cruzi. III. Duration of acquired immunity in mice initially infected with a North American strain of T. cruzi. J. Infect. Dis. 108, 213–217 (1961).
   PubMed Web of Science ®Google Scholar
• Hauschka TS. Persistence of strain-specific behavior in two strains of Trypanosoma cruzi after prolonged transfer through inbred mice. J. Parasitol. 35, 593–599 (1949).
   PubMed Web of Science ®Google Scholar
• Rego SFM. Esatado das lesoes provacadas pelo Trypanosoma cruzi chagas, 1909, no baco e no figado do camundongo branco (‘mus musculis’) com diversos graus de resistencia. J. Bras. Med.1, 599–674 (1959).
   Google Scholar
• Basombrio MA. Trypanosoma cruzi: partial prevention of the natural infection of guinea-pigs with a killed parasite vaccine. Exp. Parasitol. 71, 1–8 (1990).
   PubMed Web of Science ®Google Scholar
• Goble FC, Boyd JL, Grim WM, Konrath M. Vaccination against experimental Chagas’ disease with homogenates of culture forms of Trypanosoma cruzi. J. Parasitol. 50, 19 (1964).
   Google Scholar
• Seneca H, Peer PM. Immuno-biological properties of chagatoxin (lipopolysaccharide). Trans. R. Soc. Trop. Med. Hyg. 60, 610–620 (1966).
   PubMedGoogle Scholar
• Gonzalez Cappa SM, Pesce UJ, Cantarella AI, Schmunis GA. Trypanosoma cruzi: protection of mice with epimastigote antigens from immunologically different parasite strains. Exp. Parasitol. 35, 179–186 (1974).
   PubMedGoogle Scholar
• Roberson EL, Hanson WL. Correspondence: Transfer of immunity to T. cruzi. Trans. R. Soc. Trop. Med. Hyg. 68, 338 (1974).
   PubMedGoogle Scholar
• Okanla EO, Stumpf JL, Dusanic DG. Resistance of mice immunized with irradiated and lyophilized stages of Trypanosoma cruzi to infections with metacyclics. Int. J. Parasitol. 12, 251–256 (1982).
   PubMedGoogle Scholar
• Garcia CA, Oliveira EC, Sakurada JK, Santos LM. Protective immunity induced by a Trypanosoma cruzi soluble extract antigen in experimental Chagas’ disease. Role of interferon-γ. Immunol. Invest. 29, 1–12 (2000).
   PubMedGoogle Scholar
• Gonzalez Cappa SM, Bronzina A, Katzin AM et al. Antigens of subcellular fractions of Trypanosoma cruzi. III. Humoral immune response and histopathology of immunized mice. J. Protozool. 27, 467–471 (1980).
   PubMedGoogle Scholar
• Ruiz AM, Esteva M, Riarte A, Subias E, Segura EL. Immunoprotection of mice against Trypanosoma cruzi with a lyophilized flagellar fraction of the parasite plus adjuvant. Immunol. Lett.12, 1–4 (1986).
   PubMedGoogle Scholar
• Ruiz AM, Esteva M, Cabeza Meckert P, Laguens RP, Segura EL. Protective immunity and pathology induced by inoculation of mice with different subcellular fractions of Trypanosoma cruzi. Acta. Trop. 42, 299–309 (1985).
   PubMedGoogle Scholar
• Collier WA. Uber Immunitat bei der Chagas krankheit der weissen mau. Z. Hyg. Infektionskr. 11288–92 (1931).
   Google Scholar
• Fernandes JF, Castellani O, Okumura M. Histopathology of the heart and muscles in mice immunized against Trypanosoma cruzi. Rev. Inst. Med. Trop. Sao Paulo 8, 151–156 (1966).
   PubMedGoogle Scholar
• Hauschka TS, Goodwin MB et al. Immunological relationship between seven strains of Trypanosoma cruzi and its application in the diagnosis of Chagas’ disease. Am. J. Trop. Med. Hyg. 30, 1–16 (1950).
   PubMed Web of Science ®Google Scholar
• Pizzi T, Prager R. Immunity to infection induced by culture of Trypanosoma cruzi of atenuated virulence; preliminary communication. Bol. Inf. Parasit. Chil. 7, 20–21 (1952).
   PubMedGoogle Scholar
• Brener Z, Chiari E. Susceptibility of different strains of Trypanosoma cruzi to various chemotherapeutic agents. Rev. Inst. Med. Trop. Sao Paulo 9, 197–207 (1967).
   PubMedGoogle Scholar
• Menezes H. The use of adjuvants in the vaccination of mice with lyophilized ‘Trypanosoma cruzi’. Hospital (Rio J) 68, 1341–1346 (1965).
   Google Scholar
• Menezes H. Protective effect of an avirulent (cultivated) strain of Trypanosoma cruzi against experimental infection in mice. Rev. Inst. Med. Trop. Sao Paulo 10, 1–4 (1968).
   PubMedGoogle Scholar
• Menezes H. Active immunization of mice with the avirulent Y strain of Trypanosoma cruzi against heterologous virulent strains of the the same parasite. Rev. Inst. Med. Trop. Sao Paulo 11, 335–342 (1969).
   PubMedGoogle Scholar
• Menezes H. Active immunization of dogs with a non-virulent strain of Trypanosoma cruzi. Rev. Inst. Med. Trop. Sao Paulo 11, 258–263 (1969).
   PubMedGoogle Scholar
• Revelli S, Basombrio MA, Valenti JL et al. Evaluation of an attenuated Trypanosoma cruzi strain in rats. Analysis of survival, parasitemia and tissue damage. Medicina 53, 39–43 (1993).
   PubMed Web of Science ®Google Scholar
• Araujo Z, El Bouhdidi A, Heremans H et al. Vaccination of mice with a combination of BCG and killed Leishmania promastigotes reduces acute Trypanosoma cruzi infection by promoting an IFN-γ response. Vaccine 17, 957–964 (1999).
   PubMedGoogle Scholar
• Kierszenbaum F, Ferraresi RW. Enhancement of host resistance against Trypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide. Infect. Immun. 25, 273–278 (1979).
   PubMedGoogle Scholar
• Abath FG, Coutinho EM, Montenegro SM, Gomes YM, Carvalho AB. The use of non-specific immunopotentiators in experimental Trypanosoma cruzi infection. Trans. R. Soc. Trop. Med. Hyg. 82, 73–76 (1988).
   PubMedGoogle Scholar
• Tarleton RL, Koller BH, Latour A, Postan M. Susceptibility of β 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 356, 338–340 (1992).
   PubMed Web of Science ®Google Scholar
• Bachmaier K, Neu N, Pummerer C et al. iNOS expression and nitrotyrosine formation in the myocardium in response to inflammation is controlled by the interferon regulatory transcription factor 1. Circulation 96, 585–591 (1997).
   PubMed Web of Science ®Google Scholar
• Martins GA, Cardoso MA, Aliberti JC, Silva JS. Nitric oxide-induced apoptotic cell death in the acute phase of Trypanosoma cruzi infection in mice. Immunol. Lett.63, 113–120 (1998).
   PubMed Web of Science ®Google Scholar
• Aliberti JC, Souto JT, Marino AP et al. Modulation of chemokine production and inflammatory responses in interferon-γ- and tumor necrosis factor-R1-deficient mice during Trypanosoma cruzi infection. Am. J. Pathol. 158, 1433–1440. (2001).
   PubMedGoogle Scholar
• Chandra M, Tanowitz HB, Petkova SB et al. Significance of inducible nitric oxide synthase in acute myocarditis caused by Trypanosoma cruzi (Tulahuen strain). Int. J. Parasitol. 32, 897–905 (2002).
   PubMed Web of Science ®Google Scholar
• Silva JS, Vespa GN, Cardoso MA, Aliberti JC, Cunha FQ. Tumor necrosis factor α mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected γ interferon-activated macrophages. Infect. Immun. 63, 4862–4867 (1995).
   PubMed Web of Science ®Google Scholar
• Cardillo F, Voltarelli JC, Reed SG, Silva JS. Regulation of Trypanosoma cruzi infection in mice by γ interferon and interleukin-10: role of NK cells. Infect. Immun. 64, 128–134 (1996).
   PubMed Web of Science ®Google Scholar
• Cardillo F, Nomizo A, Postol E, Mengel J. NK1.1 cells are required to control T-cell hyperactivity during Trypanosoma cruzi infection. Med. Sci. Monit. 10, BR259–267 (2004).
   Google Scholar
• Vespa GN, Cunha FQ, Silva JS. Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect. Immun. 62, 5177–5182 (1994).
   PubMed Web of Science ®Google Scholar
• Brener Z, Gazzinelli RT. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas’ disease. Int. Arch. Allergy Immunol. 114, 103–110 (1997).
   PubMed Web of Science ®Google Scholar
• Garg N, Tarleton RL. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect. Immun. 70, 5547–5555 (2002).
   PubMed Web of Science ®Google Scholar
• Wizel B, Nunes M, Tarleton RL. Identification of Trypanosoma cruzi trans-sialidase family members as targets of protective CD8+ TC1 responses. J. Immunol. 159, 6120–6130 (1997).
   PubMed Web of Science ®Google Scholar
• Krautz GM, Kissinger JC, Krettli AU. The targets of the lytic antibody response against Trypanosoma cruzi. Parasitol. Today 16, 31–34 (2000).
   PubMedGoogle Scholar
• Umezawa ES, Shikanai-Yasuda MA, Stolf AM. Changes in isotype composition and antigen recognition of anti-Trypanosoma cruzi antibodies from acute to chronic Chagas disease. J. Clin. Lab. Anal. 10, 407–413 (1996).
   PubMedGoogle Scholar
• Antas PR, Azevedo EN, Luz MR et al. A reliable and specific enzyme-linked immunosorbent assay for the capture of IgM from human chagasic sera using fixed epimastigotes of Trypanosoma cruzi. Parasitol. Res. 86, 813–820 (2000).
   PubMedGoogle Scholar
• Reis MM, Higuchi MdL, Benvenuti LA et al. An in situ quantitative immunohistochemical study of cytokines and IL-2R+ in chronic human chagasic myocarditis: correlation with the presence of myocardial Trypanosoma cruzi antigens. Clin. Immunol. Immunopathol. 83, 165–172 (1997).
   PubMed Web of Science ®Google Scholar
• Higuchi MD, Ries MM, Aiello VD et al. Association of an increase in CD8+ T-cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am. J. Trop. Med. Hyg. 56, 485–489 (1997).
   PubMed Web of Science ®Google Scholar
• Wizel B, Palmieri M, Mendoza C et al. Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T-lymphocyte responses. J. Clin. Invest. 102, 1062–1071 (1998).
   PubMed Web of Science ®Google Scholar
• Laucella SA, Postan M, Martin D et al. Frequency of interferon -γ- producing T-cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J. Infect. Dis. 189, 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Santos MA, Garg N, Tarleton RL. The identification and molecular characterization of Trypanosoma cruzi amastigote surface protein-1, a member of the trans-sialidase gene super-family. Mol. Biochem. Parasitol. 86, 1–11 (1997).
   PubMedGoogle Scholar
• Araguth MF, Rodrigues MM, Yoshida N. Trypanosoma cruzi metacyclic trypomastigotes: neutralization by the stage-specific monoclonal antibody 1G7 and immunogenicity of 90 kD surface antigen. Parasite Immunol. 10, 707–712 (1988).
   PubMedGoogle Scholar
• Ruiz AM, Esteva M, Subias E et al. Monoclonal antibodies against the flagellar fraction of epimastigotes of Trypanosoma cruzi: immunoprotection against metacyclic trypomastigotes obtained by immunization of mice with an affinity-purified antigen. Mol. Biochem. Parasitol. 39, 117–125 (1990).
   PubMedGoogle Scholar
• Fralish BH, Tarleton RL. Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine 21, 3070–3080 (2003).
   PubMed Web of Science ®Google Scholar
• Low HP, Tarleton RL. Molecular cloning of the gene encoding the 83 kDa amastigote surface protein and its identification as a member of the Trypanosoma cruzi sialidase superfamily. Mol. Biochem. Parasitol. 88, 137–149 (1997).
   PubMedGoogle Scholar
• Boscardin SB, Kinoshita SS, Fujimura AE, Rodrigues MM. Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection. Infect. Immun. 71, 2744–2757 (2003).
   PubMed Web of Science ®Google Scholar
• El-Sayed NM, Myler PJ, Bartholomeu DC et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309, 409–415 (2005).
   PubMedGoogle Scholar
• Garg N, Nunes MP, Tarleton RL. Delivery by Trypanosoma cruzi of proteins into the MHC class I antigen processing and presentation pathway. J. Immunol. 158, 3293–3302 (1997).
   PubMedGoogle Scholar
• Kumar S, Tarleton RL. Antigen-specific Th1 but not Th2 cells provide protection from lethal Trypanosoma cruzi infection in mice. J. Immunol. 166, 4596–4603 (2001).
   PubMed Web of Science ®Google Scholar
• Moutiez M, Aumercier M, Schoneck R et al. Purification and characterization of a trypanothione-glutathione thioltransferase from Trypanosoma cruzi. Biochem. J 310(Pt. 2), 433–437 (1995).
   Google Scholar
• Allaoui A, Francois C, Zemzoumi K, Guilvard E, Ouaissi A. Intracellular growth and metacyclogenesis defects in Trypanosoma cruzi carrying a targeted deletion of a Tc52 protein-encoding allele. Mol. Microbiol. 32, 1273–1286 (1999).
   PubMed Web of Science ®Google Scholar
• Tomas AM, Miles MA, Kelly JM. Overexpression of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, is associated with enhanced metacyclogenesis. Eur. J. Biochem. 244, 596–603 (1997).
   PubMedGoogle Scholar
• Norris KA. Stable transfection of Trypanosoma cruzi epimastigotes with the trypomastigote-specific complement regulatory protein cDNA confers complement resistance. Infect. Immun. 66, 2460–2465 (1998).
   PubMedGoogle Scholar
• Scott MT, Neal RA, Woods NC. Immunization of marmosets with Trypanosoma cruzi cell surface glycoprotein (GP90). Trans. R. Soc. Trop. Med. Hyg. 79, 451–454 (1985).
   PubMedGoogle Scholar
• Harth G, Mills AA, Lin T, Araujo FG. Trypanosoma cruzi glycoprotein of M(r) 56,000 characterization and assessment of its potential to protect against fatal parasite infections. Mol. Microbiol. 11, 261–271 (1994).
   PubMedGoogle Scholar
• Santori FR, Paranhos-Bacalla GS, Franco DASJ et al. A recombinant protein based on the Trypanosoma cruzi metacyclic trypomastigote 82-kilodalton antigen that induces and effective immune response to acute infection. Infect. Immun. 64, 1093–1099 (1996).
   PubMedGoogle Scholar
• Wrightsman RA, Manning JE. Paraflagellar rod proteins administered with alum and IL-12 or recombinant adenovirus expressing IL-12 generates antigen-specific responses and protective immunity in mice against Trypanosoma cruzi. Vaccine 18, 1419–1427 (2000).
   PubMedGoogle Scholar
• Wrightsman RA, Luhrs KA, Fouts D, Manning JE. Paraflagellar rod protein-specific CD8+ cytotoxic T-lymphocytes target Trypanosoma cruzi-infected host cells. Parasite Immunol. 24, 401–412 (2002).
   PubMedGoogle Scholar
• Luhrs KA, Fouts DL, Manning JE. Immunization with recombinant paraflagellar rod protein induces protective immunity against Trypanosoma cruzi infection. Vaccine 21, 3058–3069 (2003).
   PubMed Web of Science ®Google Scholar
• Sepulveda P, Hontebeyrie M, Liegeard P, Mascilli A, Norris KA. DNA-Based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection. Infect. Immun. 68, 4986–4991 (2000).
   PubMedGoogle Scholar
• Ouaissi A, Da Silva AC, Guevara AG et al. The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection. J. Immunol. 168, 6386–6374 (2001).
   Google Scholar
• Laderach D, Cerban F, Motran C, Vottero de Cima E, Gea S. Trypanosoma cruzi: the major cysteinyl proteinase (cruzipain) is a relevant immunogen of parasite acidic antigens (FIII). Int. J. Parasitol. 26, 1249–1254 (1996).
   PubMedGoogle Scholar
• Schnapp AR, Eickhoff CS, Sizemore D, Curtiss R 3rd, Hoft DF. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Infect. Immun. 70, 5065–5074 (2002).
   PubMed Web of Science ®Google Scholar
• Frank FM, Petray PB, Cazorla SI et al. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine 22, 77–86 (2003).
   PubMed Web of Science ®Google Scholar
• Costa F, Franchin G, Pereira-Chioccola VL et al. Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. Vaccine 16, 768–774 (1998).
   PubMed Web of Science ®Google Scholar
• Planelles L, Thomas MC, Alonso C, Lopez MC. DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection. Infect. Immun. 69, 6558–6563. (2001).
   PubMedGoogle Scholar
• Wizel B, Garg N, Tarleton RL. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect. Immun. 66, 5073–5081 (1998).
   PubMedGoogle Scholar
• Schnapp AR, Eickhoff CS, Scharfstein J, Hoft DF. Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection. Microbes Infect. 4, 805–813 (2002).
   PubMedGoogle Scholar
• Katae M, Miyahira Y, Takeda K et al. Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Infect. Immun. 70, 4833–4840 (2002).
   PubMedGoogle Scholar
• Miyahira Y, Akiba H, Katae M et al. Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-κ B gene for inducing antigen-specific CD8+ T-cell response by DNA and viral vector vaccination. J. Immunol. 171, 6344–6348 (2003).
   PubMed Web of Science ®Google Scholar
• Alberti E, Acosta A, Sarmiento ME et al. Specific cellular and humoral immune response in Balb/c mice immunized with an expression genomic library of Trypanosoma cruzi. Vaccine 16, 608–612 (1998).
   Google Scholar
• Dumonteil E, Escobedo-Ortegon J, Reyes-Rodriguez N, Arjona-Torres A, Ramirez-Sierra MJ. Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect. Immun. 72, 46–53 (2004).
   PubMed Web of Science ®Google Scholar
• Huygen K. Plasmid DNA vaccination. Microbes Infect. 7, 932–938 (2005).
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J. Immunol. 175, 633–639 (2005).
   PubMed Web of Science ®Google Scholar
• Schenkman S, Eichinger D, Pereira ME, Nussenzweig V. Structural and functional properties of Trypanosoma cruzi trans-sialidase. Ann. Rev. Microbiol. 48, 499–523 (1994).
   PubMed Web of Science ®Google Scholar
• Manning-Cela R, Cortes A, Gonzalez-Rey E et al. LYT1 protein is required for efficient in vitro infection by Trypanosoma cruzi. Infect. Immun. 69, 3916–3923. (2001).
   PubMedGoogle Scholar
• Maranon C, Thomas MC, Planelles L, Lopez MC. The immunization of A2/K(b) transgenic mice with the KMP11-HSP70 fusion protein induces CTL response against human cells expressing the T. cruzi KMP11 antigen: identification of A2-restricted epitopes. Mol. Immunol. 38, 279–287 (2001).
   PubMed Web of Science ®Google Scholar
• Frasch AC. Functional diversity in the trans-sialidase and mucin families in Trypanosoma cruzi. Parasitol. Today 16, 282–286. (2000).
   PubMedGoogle Scholar
• Garg N, Tarleton RL. Elicitation of protective cellular and humoral immune responses to Trypanosoma cruzi infection using DNA vaccines can be augmented with cytokines. Proceedings of the 10th International Congress of Immunology, New Delhi, India, 1421–1426 (1998).
   Google Scholar
• Vasconcelos JR, Boscardin SB, Hiyane MI et al. A DNA-priming protein-boosting regimen significantly improves Type 1 immune response but not protective immunity to Trypanosoma cruzi infection in a highly susceptible mouse strain. Immunol. Cell Biol. 81, 121–129 (2003).
   PubMedGoogle Scholar
• Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816–1820 (2000).
   PubMed Web of Science ®Google Scholar
• Etz H, Minh DB, Henics T et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl Acad. Sci. USA 99, 6573–6578 (2002).
   PubMed Web of Science ®Google Scholar
• Ross BC, Czajkowski L, Hocking D et al. Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19, 4135–4142 (2001).
   PubMed Web of Science ®Google Scholar
• Adamou JE, Heinrichs JH, Erwin AL et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect. Immun. 69, 949–958 (2001).
   PubMed Web of Science ®Google Scholar
• Bhatia V, Sinha M, Luxon B, Garg N. Utility of Trypanosoma cruzi sequence database for the identification of potential vaccine candidates: In silico and in vitro screening. Infect. Immun. 72, 6245–6254 (2004).
   PubMed Web of Science ®Google Scholar
• Corral RS, Petray PB. CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi. Vaccine 19, 234–242 (2000).
   PubMedGoogle Scholar
• Dhiman N, Bonilla R, O’Kane DJ, Poland GA. Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine 20, 22–30 (2001).
   PubMed Web of Science ®Google Scholar
• Rathod PK, Ganesan K, Hayward RE, Bozdech Z, DeRisi JL. DNA microarrays for malaria. Trends Parasitol. 18, 39–45 (2002).
   PubMed Web of Science ®Google Scholar
• Grifantini R, Bartolini E, Muzzi A et al. Gene expression profile in Neisseria meningitidis and Neisseria lactamica upon host-cell contact: from basic research to vaccine development. Ann. NY Acad. Sci. 975, 202–216 (2002).
   PubMed Web of Science ®Google Scholar
• Chen L, Martinez O, Overbergh L et al. Early upregulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin. Exp. Immunol. 138, 375–387 (2004).
   PubMed Web of Science ®Google Scholar
• Prabhakar U, Conway TM, Murdock P et al. Correlation of protein and gene expression profiles of inflammatory proteins after endotoxin challenge in human subjects. DNA Cell. Biol. 24, 410–431 (2005).
   PubMedGoogle Scholar
• Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol.75, 7059–7066 (2001).
   PubMed Web of Science ®Google Scholar
• Dorn A, Zhao H, Granberg F et al. Identification of specific cellular genes upregulated late in adenovirus Type 12 infection. J. Virol.79, 2404–2412 (2005).
   PubMedGoogle Scholar
• Sandler NG, Mentink-Kane MM, Cheever AW, Wynn TA. Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for Th1 and Th2 responses in tissue repair. J. Immunol. 171, 3655–3667 (2003).
   PubMed Web of Science ®Google Scholar
• Cassat JE, Dunman PM, McAleese F et al. Comparative genomics of Staphylococcus aureus musculoskeletal isolates. J Bacteriol 187, 576–592 (2005).
   Google Scholar
• Minning TA, Bua J, Garcia GA, McGraw RA, Tarleton RL. Microarray profiling of gene expression during trypomastigote to amastigote transition in Trypanosoma cruzi. Mol. Biochem. Parasitol. 131, 55–64 (2003).
   PubMedGoogle Scholar
• Baptista CS, Vencio RZ, Abdala S et al. DNA microarrays for comparative genomics and analysis of gene expression in Trypanosoma cruzi. Mol. Biochem. Parasitol. 138, 183–194 (2004).
   PubMedGoogle Scholar
• Gorelik G, Cremaschi G, Borda E, Sterin-Borda L. Trypanosoma cruzi antigens downregulate T-lymphocyte proliferation by muscarinic cholinergic receptor-dependent release of PGE2. Acta. Physiol. Pharmacol. Ther. Latinoam. 48, 115–123 (1998).
   PubMedGoogle Scholar
• Kierszenbaum F, de Diego JL, Fresno M, Sztein MB. Inhibitory effects of the Trypanosoma cruzi membrane glycoprotein AGC10 on the expression of IL-2 receptor chains and secretion of cytokines by subpopulations of activated human T-lymphocytes. Eur. J. Immunol. 29, 1684–1691 (1999).
   Google Scholar
• Sztein MB, Kierszenbaum F. Mechanisms of development of immunosuppression during Trypanosoma infections. Parasitol. Today 9, 424–428 (1993).
   PubMedGoogle Scholar
• Ouaissi A, Guevara-Espinoza A, Chabe F, Gomez-Corvera R, Taibi A. A novel and basic mechanism of immunosuppression in Chagas’ disease: Trypanosoma cruzi releases in vitro and in vivo a protein which induces T-cell unresponsiveness through specific interaction with cysteine and glutathione. Immunol. Lett.48, 221–224 (1995).
   PubMedGoogle Scholar